A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity

Descripción del Articulo

Influenza is a highly contagious disease. There are some historical descriptions of this condition by ancient Greek physicians, and the etiological agents have been known only for the last eight decades. The causative agent is the influenza virus, which has three main types: A, B, and C. Type A is c...

Descripción completa

Detalles Bibliográficos
Autores: Osores Plenge, Fernando, Gómez Benavides, Jorge, Suarez Ognio, Luis, Cabezas Sánchez, César, Alave Rosas, Jorge, Maguiña Vargas, Ciro
Formato: artículo
Fecha de Publicación:2009
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:ojs.pkp.sfu.ca:article/1507
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/1507
Nivel de acceso:acceso abierto
Materia:Influenza
Antigenic drift
Neuraminidase
Hemaglutinin
Novel influenza A H1N1
Pandemic
id REVCMP_236ac26370510522fdba53dcd0e755ed
oai_identifier_str oai:ojs.pkp.sfu.ca:article/1507
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
dc.title.none.fl_str_mv A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
Un nuevo virus A/H1N1, una nueva pandemia: Influenza un riesgo permanente para una humanidad globalizada
title A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
spellingShingle A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
Osores Plenge, Fernando
Influenza
Antigenic drift
Neuraminidase
Hemaglutinin
Novel influenza A H1N1
Pandemic
title_short A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
title_full A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
title_fullStr A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
title_full_unstemmed A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
title_sort A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanity
dc.creator.none.fl_str_mv Osores Plenge, Fernando
Gómez Benavides, Jorge
Suarez Ognio, Luis
Cabezas Sánchez, César
Alave Rosas, Jorge
Maguiña Vargas, Ciro
author Osores Plenge, Fernando
author_facet Osores Plenge, Fernando
Gómez Benavides, Jorge
Suarez Ognio, Luis
Cabezas Sánchez, César
Alave Rosas, Jorge
Maguiña Vargas, Ciro
author_role author
author2 Gómez Benavides, Jorge
Suarez Ognio, Luis
Cabezas Sánchez, César
Alave Rosas, Jorge
Maguiña Vargas, Ciro
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Influenza
Antigenic drift
Neuraminidase
Hemaglutinin
Novel influenza A H1N1
Pandemic
topic Influenza
Antigenic drift
Neuraminidase
Hemaglutinin
Novel influenza A H1N1
Pandemic
description Influenza is a highly contagious disease. There are some historical descriptions of this condition by ancient Greek physicians, and the etiological agents have been known only for the last eight decades. The causative agent is the influenza virus, which has three main types: A, B, and C. Type A is capable of circulating within many different biological reservoirs, including humans, swine, and birds. It also has high genetic variability, which allows it to have minor antigenic drifts or mutations which are responsible of epidemics in humans. Sometimes changes are quite marked, leading to pandemics.In a globalized world, with more than 6 billion inhabitants, with many social inequities and evident climate changes, influenza viruses are a permanent risk for mankind.Clinical features for the different viral subtypes may vary from subtle infections to full blown and severe, life-threatening forms. Event with the great advances in diagnostics and immunization, the manufacture and distribution of new diagnostic kits may take some time, and new vaccines are not always readily available. Specific therapies against influenza are not well developed. There are two groups of drugs, the so called adamantane derivatives, such as amantadine and rimantadine, and the neuraminidase inhibitors, such as oseltamivir and zanamivir. Most vulnerable areas for the new flu pandemics include developing countries, particularly the poorest ones, so that the greatest effort must be made for helping these areas.
publishDate 2009
dc.date.none.fl_str_mv 2009-06-30
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1507
url https://amp.cmp.org.pe/index.php/AMP/article/view/1507
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1507/943
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol 26 No 2 (2009); 97 - 130
ACTA MEDICA PERUANA; Vol. 26 Núm. 2 (2009); 97 - 130
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1816075108011212800
spelling A new virus A/H1N1, a new pandemic: a continuing risk to a globalized humanityUn nuevo virus A/H1N1, una nueva pandemia: Influenza un riesgo permanente para una humanidad globalizadaOsores Plenge, FernandoGómez Benavides, JorgeSuarez Ognio, LuisCabezas Sánchez, César Alave Rosas, JorgeMaguiña Vargas, Ciro InfluenzaAntigenic driftNeuraminidaseHemaglutininNovel influenza A H1N1PandemicInfluenza is a highly contagious disease. There are some historical descriptions of this condition by ancient Greek physicians, and the etiological agents have been known only for the last eight decades. The causative agent is the influenza virus, which has three main types: A, B, and C. Type A is capable of circulating within many different biological reservoirs, including humans, swine, and birds. It also has high genetic variability, which allows it to have minor antigenic drifts or mutations which are responsible of epidemics in humans. Sometimes changes are quite marked, leading to pandemics.In a globalized world, with more than 6 billion inhabitants, with many social inequities and evident climate changes, influenza viruses are a permanent risk for mankind.Clinical features for the different viral subtypes may vary from subtle infections to full blown and severe, life-threatening forms. Event with the great advances in diagnostics and immunization, the manufacture and distribution of new diagnostic kits may take some time, and new vaccines are not always readily available. Specific therapies against influenza are not well developed. There are two groups of drugs, the so called adamantane derivatives, such as amantadine and rimantadine, and the neuraminidase inhibitors, such as oseltamivir and zanamivir. Most vulnerable areas for the new flu pandemics include developing countries, particularly the poorest ones, so that the greatest effort must be made for helping these areas.La influenza es una enfermedad altamente infectocontagiosa de la cual se tienen registros históricos descriptivos desde la época griega y de certeza etiológica tan solo hace casi ocho décadas atrás. Su agente causal es el virus del influenza de los que se conoce existen tres grandes tipos: A B y C. El tipo A tiene la propiedad de circular por diversos reservorios biológicos, tales como el hombre, los cerdos y las aves, entre otros. Representa además una elevada variabilidad genética lo que le permite continuos cambios o derivas antigénicas menores responsables de la influenza humanas epidémicas y a veces reordenamientos amplios con cambios antigénicos mayores los que originan la temida influenza pandémica.En un mundo cada vez mas globalizado, con una población superior a los seis mil millones de personas, marcado por grandes inequidades sociales y con cambios climáticos evidentes, los virus de la influenza serán un riesgo permanente para la seguridad de la humanidad.La clínica de los diversos subtipos virales pueden balancearce desde las formas inaparentes hasta las formas graves de gripe o influenza, dependiendo de la virulencia del subtipo viral infectante y del huesped. Aunque nuestra tecnología diagnóstica y de inmunización ha avanzado sorprendentemente, la preparación y disposición de los nuevos kits diagnósticos suelen tardar al principio y en el caso de las vacunas estas no están disponibles para el un nuevo subtipo viral pandémico en el momento que se las necesita. El desarrollo de antivirales contra la gripe no es notorio, contándose aprobados para uso humano los amadantanes como la amantadina y la rimantadina y los inhibidores de la neuraminidasa como oseltamivir y sanamivir principalmente. Claramente los más vulnerables en este contexto son los países en vías de desarrollo y en especial aquellos mas pobres, hecho que nos debería llamar a una profunda reflexión.Colegio Médico del Perú2009-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/1507ACTA MEDICA PERUANA; Vol 26 No 2 (2009); 97 - 130ACTA MEDICA PERUANA; Vol. 26 Núm. 2 (2009); 97 - 1301728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1507/943Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:ojs.pkp.sfu.ca:article/15072023-07-06T06:01:52Z
score 13.871978
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).